Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
Incyte delivered a strong Q1 with total revenue of $1.27 billion, up 21% year-over-year, driven by 20% growth in net sales to $1.10 billion. The pipeline generated significant catalysts, including positive Phase 3 results for povorcitinib in nonsegmental vitiligo and the initiation of a pivotal Phase 3 study for INCB161734 in pancreatic cancer.
Key figures
- Eps
- 1.47
- Revenue
- $1.27 billion
- Drug Name
- povorcitinib
- Guidance
- Total net sales $4.77 - $4.94 billion
- Revenue Yoy
- 21%
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.